Aptus Pharma Limited has filed its mandatory compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the half year ended March 31, 2026. The pharmaceutical company submitted the certificate to BSE Limited on April 11, 2026, fulfilling its regulatory obligations for the reporting period.

Regulatory Compliance Details

The certificate covers the period from January 1, 2026 to March 31, 2026, and was prepared by Accurate Securities & Registry Private Limited, which serves as Aptus Pharma's Registrar and Share Transfer Agent. The compliance filing confirms adherence to SEBI regulations governing dematerialisation processes and depositories.

Certificate Confirmation

Accurate Securities & Registry Private Limited confirmed that all securities received from depository participants for dematerialisation during the specified period were processed within the stipulated time limits as required under SEBI regulations. The registrar verified that securities were either accepted or rejected on technical grounds as appropriate, and all processes were completed in compliance with regulatory requirements.

The certificate also confirms that securities received for dematerialisation were properly mutilated and cancelled after due verification, following operational procedures. Additionally, the names of depositories were substituted in the security holder's list as registered owners within the prescribed time limits.

Company and Registrar Information

Tejash Hathi, Managing Director of Aptus Pharma Limited (DIN: 03151221), signed the submission letter to BSE. Accurate Securities & Registry Private Limited, registered with SEBI under registration number INR000004173, operates from its registered office in Ahmedabad and maintains working hours from Monday to Friday, 11.30 AM to 5.00 PM with a lunch break from 1.30 PM to 2.30 PM.

This regulatory filing demonstrates Aptus Pharma's commitment to maintaining compliance with SEBI regulations and ensuring proper handling of dematerialisation processes through its appointed registrar and share transfer agent.

Aptus Pharma Limited's board of directors approved significant corporate restructuring proposals during its meeting held on March 24, 2026. The pharmaceutical company's board sanctioned an authorized share capital enhancement and recommended a 3:2 bonus equity shares issue, with comprehensive regulatory compliance measures in place.

Authorized Share Capital Enhancement

The board approved a substantial increase in the company's authorized share capital structure, subject to shareholder approval. The enhancement represents a strategic expansion to support future growth initiatives and corporate flexibility.

Bonus Equity Shares Recommendation

The board recommended issuing bonus equity shares to existing shareholders in a 3:2 ratio. The bonus shares will be issued by capitalizing ₹10,29,00,000 from the securities premium account, with adequate reserves available for the proposed capitalization.

Share Capital Structure Impact

The bonus issue will significantly transform the company's paid-up share capital structure, with the total number of shares increasing substantially post-implementation.

Postal Ballot and E-Voting Process

The board approved the postal ballot notice along with explanatory statements for both resolutions. Central Depository Services Limited (CDSL) has been appointed as the e-voting agency, with a scrutinizer designated for conducting the process transparently. The company published newspaper advertisements on March 27, 2026, confirming the electronic dispatch of postal ballot notices to eligible shareholders.

Regulatory Compliance and Timeline

The company has obtained statutory auditor certification confirming adequate securities premium reserves of ₹10,67,63,656 as of March 24, 2026. The proposed bonus shares are expected to be credited within two months from board approval, on or before May 23, 2026. Managing Director Tejash Hathi (DIN: 03151221) signed the regulatory communication, with the board meeting conducted from 5:00 PM to 7:15 PM on March 24, 2026. The postal ballot notice has been made available on the company's website and BSE platform for shareholder access.